Cipla Ltd

BSE :500087 NSE :CIPLA Sector : Pharmac..
1,515.20
Change: 18.80(1.26%)
Buy Sell SIP
52 week Low
1,317.25
52 week High
1,702.05
Day low
1,486
Day high
1,522
Prev Close
1,496.40
Open
1,498.00
6M return
-3.01%
1Y return
10.18%
MCap(Rs. in Cr.)
1,19,672.70
Total Volume
12,11,601
Face Value : 2
Listed Since
PE Ratio

Is the price-earnings ratio for valuing a company that measures its current share price relative to its earnings per share.

P/E RATIO
23.97863
EPS

The earnings per share ratio is a portion of company's net profit allocated for each outstanding share. It is calculated by deducting preferred stock divided from the net income of the company divided by the number of outstanding shares.

EPS
61.78
PRICE/BOOK

Price-to-book ratio is used to compared the company's current market price with its book value.

PRICE/BOOK
4.31
Deliverable

These are the acutal number of shares that are traded on delivery based, meaning transfered from one person to another during the day's trade.

DELIVERABLES
53.28%
DIV YIELD.(%)

Dividend Yield measures the quantum of cash dividends paid to shareholders in a financial year relative to the market value of the per share.

DIV YIELD.(%)
0.88

Company Details

Check out the key parameters of the company to understand the financial health and stock performance

Key Level

Resistance 1
1508.80
Resistance 2
1521.20
Support 1
1474.20
Support 2
1452.00

Moving Average

20 Days
1473.86
50 Days
1462.16
100 Days
1468.53
200 Days
1518.41
Growth in 3 years

Sales
18.43%

Sales Industry Avg
16.38%

PAT
62.35%

PAT Industry Avg
37.18%

Dec 2024
( in Cr.)		Sep 2024
( in Cr.)		Jun 2024
( in Cr.)		Mar 2024
( in Cr.)		FY 2024
( in Cr.)
Sales7,072.977,051.026,693.946,163.2425,774.09
Gross Profit2,195.892,060.801,858.041,547.606,752.92
Operating Profit00000
Profit Before Tax1,921.411,765.021,607.561,445.535,701.90
Tax337.69459431.27511.131,546.59
Profit After Tax1,583.721,306.021,176.29934.404,155.31
Growth in 3 years

Total Asset Growth
23.17%

Total Liabilities growth
23.17%

Reserves Change
28.36%

Mar 2024
( in Cr.) 		Mar 2023
( in Cr.) 		Mar 2022
( in Cr.) 		Mar 2021
( in Cr.) 		Mar 2019
( in Cr.)
Share Capital161.47161.43161.36161.29161.14
Reserves And Surplus26,544.9623,246.3520,680.3318,165.2414,851.14
Investments5,449.223,662.382,550.602,710.052,554.14
Total Debt818.421,071.091,307.832,292.324,908.40
Total Liabilities27,620.7524,784.6322,425.2120,877.9120,252.65
Total Assets27,620.7524,784.6322,425.2120,877.9120,252.65
425%
2023
650%
2024 2025
2026


Relative to Sensex rtn in 3 year
26.74%

Relative to Nifty rtn in 3 year
21.93%



1 Year (%)2 Year (%)3 Year (%)
Cipla106747
Bse Sensex83137
Nifty 5083539
Nifty 50064545

Peer Companies

A quick glance on how stocks from the same sector have performed along with some key parameters

Cipla
1,515.20
Change: 18.80 (1.26%)
1 Year return
10.18%
Risk (Std Dev)
0.04%
PE Ratio
23.97863
MCap( in Cr.)
1,19,672.70
BUY SELL
Sun Pharma.Inds.
1,751.50
Change: 58.40 (3.45%)
1 Year return
13.91%
Risk (Std Dev)
0.07%
PE Ratio
34.68572
MCap( in Cr.)
4,09,086.61
BUY SELL
Divi`s Lab.
5,640.00
Change: -114.00 (-1.98%)
1 Year return
49.83%
Risk (Std Dev)
0.06%
PE Ratio
73.62253
MCap( in Cr.)
1,52,232.96
BUY SELL
Torrent Pharma.
3,254.80
Change: 32.10 (1.00%)
1 Year return
28.26%
Risk (Std Dev)
0.07%
PE Ratio
58.61778
MCap( in Cr.)
1,09,035.45
BUY SELL
Mankind Pharma
2,581.60
Change: 61.60 (2.44%)
1 Year return
13.18%
Risk (Std Dev)
0.10%
PE Ratio
49.06831
MCap( in Cr.)
1,00,095.68
BUY SELL
View More

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

 

If I had made
investment of  
in
Months Ago
My investment would be worth 1,10,180.30 with a Gain of 10.18%

Our Research Reports

Stocks and sector-wise Research Reports by HDFC securities help you analyse, understand and take a informed investment decision.

Institutional Reports 26 Jan 2022 7:53 AM
HSIE Results Daily: Cipla, Torrent Pharma, Shriram Transport Finance Company, Supreme Industries, APL Apollo, Federal Bank, IndiaMART InterMESH, Zensar Technologies, Teamlease Services, Sudarshan Chemical, Deccan Cements
Cipla: Cipla’s Q3 results came largely in line with our estimates as strong growth trends in India and the US were partially offset by weak performance in other markets. India business continues to r..
Institutional Reports 28 Oct 2021 7:15 AM
HSIE Results Daily: ITC, Larsen & Toubro, Maruti Suzuki, SBI Life Insurance, IndusInd Bank, Cipla, Torrent Pharma, ABB India, Persistent Systems, TTK Prestige, Zensar Technologies, Mahanagar Gas, Mahindra Lifespaces, PSP Projects
ITC: ITC delivered an in-line revenue growth with a few positives in key segments. Revenue was up 12% YoY with cigarettes/FMCG/hotels/agri/paper growing 10/6/260/-7/25% YoY. Cigarette revenue growth ..
Institutional Reports 27 Oct 2021 9:10 AM
Cipla (Results Review 2QFY22): In-line quarter; upbeat on outlook. Maintain BUY
Cipla’s Q2 results were largely in line with estimates as strong growth trends in India, South Africa, and EM markets were partially offset by lower gross margin (~80-100bps impact, inventory provisi..
View More

Corporate Action

Find out the historical dividend payout and other corporate actions including bonus, stock split and rights issue etc.

D
2023
D
2024
2025

Our Research Analysis

Created with Highstock 5.0.7Values19. Aug2. Sep16. Sep30. Sep14. Oct28. Oct11. Nov25. Nov9. Dec23. Dec6. Jan20. Jan3. Feb17. Feb3. Mar17. Mar31. Mar14. Apr13501400145015001550160016501700
As of today
0%
Target Achived
This call still has potential to give significant positive returns

Potential Upside
20.05%
Buy Call with 3 QUARTER(s) time frame
CMP : 1515.20
Target : 1819
Stop Loss : 0
Reco Price : 1576.10
Reco Date :19 Aug 2024
Call Type :PICK OF THE WEEK


FnO

A snapshot on how the stock has performed in the derivatives segment on a real-time basis.

Cipla Ltd 1,511.20 Chg: 16.00(1.07%) Expiry Month 24 Apr 2025
Day's Low
1,494.60
Day's High
1,520.10
Day’s Open
1,496.00
Prev Close
1,495.20
Volume
18,37,225
OI
1,14,31,550
OI Change (%)
-2.63
View More

News

Stay tuned to the latest developments and happenings in the company.

Cipla allots 23,282 equity shares under ESOS

Cipla has allotted 23,282 fully paid-up equity shares of Rs 2 each, pursuant to exercise of employee stock options under the Employee Stock Option Sch....

17 Apr 2025 16:12

Cipla receives USFDA approval for Protein-bound Paclitaxel for Injectable Suspension

Cipla has received final approval from the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitte....

11 Apr 2025 09:27

Cipla to table results

Cipla will hold a meeting of the Board of Directors of the Company on 13 May 2025.Powered by Capital Market - Live News

08 Apr 2025 09:40

Cipla consolidated net profit rises 48.74% in the December 2024 quarter

Net profit of Cipla rose 48.74% to Rs 1570.51 crore in the quarter ended December 2024 as against Rs 1055.90 crore during the previous quarter ended D....

28 Jan 2025 16:57

Cipla consolidated net profit rises 15.18% in the September 2024 quarter

Net profit of Cipla rose 15.18% to Rs 1302.53 crore in the quarter ended September 2024 as against Rs 1130.91 crore during the previous quarter ended ....

29 Oct 2024 15:32

Cipla consolidated net profit rises 18.27% in the June 2024 quarter

Net profit of Cipla rose 18.27% to Rs 1177.64 crore in the quarter ended June 2024 as against Rs 995.70 crore during the previous quarter ended June 2....

26 Jul 2024 16:06

View More
Subscribe for our
newsletter
Open Account Now